| Primary |
| Drug Use For Unknown Indication |
45.6% |
| Non-small Cell Lung Cancer |
10.5% |
| Breast Cancer |
8.2% |
| Colorectal Cancer Metastatic |
4.8% |
| Colon Cancer |
4.6% |
| Colorectal Cancer |
3.6% |
| Breast Cancer Metastatic |
2.6% |
| Ovarian Cancer |
2.3% |
| Renal Cell Carcinoma |
2.0% |
| Hypertension |
1.9% |
| Glioblastoma |
1.8% |
| Ovarian Epithelial Cancer |
1.7% |
| Glioblastoma Multiforme |
1.7% |
| Pain |
1.5% |
| Rectal Cancer |
1.5% |
| Colon Cancer Metastatic |
1.5% |
| Product Used For Unknown Indication |
1.4% |
| Metastatic Renal Cell Carcinoma |
1.1% |
| Prophylaxis |
1.0% |
| Nausea |
0.9% |
|
| Death |
14.3% |
| Pyrexia |
12.8% |
| Vomiting |
11.3% |
| Sepsis |
5.5% |
| Thrombocytopenia |
4.8% |
| General Physical Health Deterioration |
4.7% |
| Disease Progression |
4.5% |
| Renal Failure |
4.3% |
| Pulmonary Embolism |
3.9% |
| Small Intestinal Obstruction |
3.8% |
| Pneumonia |
3.6% |
| Mucosal Inflammation |
3.4% |
| Sudden Death |
3.3% |
| Anaemia |
3.2% |
| Renal Failure Acute |
3.1% |
| White Blood Cell Count Decreased |
3.0% |
| Weight Decreased |
2.8% |
| Convulsion |
2.7% |
| Urinary Tract Infection |
2.4% |
| Neutropenia |
2.4% |
|
| Secondary |
| Breast Cancer |
15.3% |
| Non-small Cell Lung Cancer |
10.9% |
| Drug Use For Unknown Indication |
10.6% |
| Product Used For Unknown Indication |
7.8% |
| Colorectal Cancer Metastatic |
7.2% |
| Colorectal Cancer |
6.8% |
| Colon Cancer |
6.1% |
| Hypertension |
4.7% |
| Prophylaxis |
4.4% |
| Ovarian Cancer |
3.0% |
| Rectal Cancer |
2.8% |
| Breast Cancer Metastatic |
2.7% |
| Sarcoma |
2.6% |
| Renal Cell Carcinoma |
2.4% |
| Colon Cancer Metastatic |
2.4% |
| Pain |
2.3% |
| Glioblastoma |
2.1% |
| Glioblastoma Multiforme |
2.0% |
| Rhabdomyosarcoma |
2.0% |
| Nausea |
1.8% |
|
| Vomiting |
15.0% |
| Pyrexia |
8.5% |
| Pulmonary Embolism |
7.8% |
| Thrombocytopenia |
6.8% |
| Death |
6.6% |
| Sepsis |
5.9% |
| Diarrhoea |
4.6% |
| Pneumonia |
4.6% |
| Hypertension |
4.5% |
| Urinary Tract Infection |
3.8% |
| Neutropenia |
3.6% |
| Febrile Neutropenia |
3.6% |
| Respiratory Failure |
3.6% |
| Weight Decreased |
3.3% |
| Nausea |
3.1% |
| Dehydration |
3.0% |
| Syncope |
3.0% |
| Thrombosis |
3.0% |
| Septic Shock |
2.9% |
| Disease Progression |
2.8% |
|
| Concomitant |
| Breast Cancer |
21.1% |
| Product Used For Unknown Indication |
11.6% |
| Colon Cancer |
8.8% |
| Non-small Cell Lung Cancer |
7.7% |
| Colorectal Cancer Metastatic |
6.5% |
| Colorectal Cancer |
6.1% |
| Breast Cancer Metastatic |
4.7% |
| Rectal Cancer |
3.6% |
| Drug Use For Unknown Indication |
3.5% |
| Renal Cell Carcinoma |
2.9% |
| Nausea |
2.7% |
| Metastatic Renal Cell Carcinoma |
2.6% |
| Pain |
2.6% |
| Colon Cancer Metastatic |
2.5% |
| Prophylaxis |
2.4% |
| Premedication |
2.4% |
| Hypertension |
2.3% |
| Metastases To Bone |
2.1% |
| Glioblastoma |
2.0% |
| Non-small Cell Lung Cancer Stage Iiib |
1.8% |
|
| Vomiting |
15.8% |
| Thrombocytopenia |
9.2% |
| Febrile Neutropenia |
8.5% |
| White Blood Cell Count Decreased |
7.3% |
| Death |
6.2% |
| Pulmonary Embolism |
5.8% |
| Alanine Aminotransferase Increased |
5.0% |
| Neutropenia |
3.8% |
| Osteonecrosis Of Jaw |
3.8% |
| Rash |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| Neutrophil Count Decreased |
3.5% |
| Pneumonia |
3.5% |
| Cystoid Macular Oedema |
3.1% |
| Neuropathy Peripheral |
3.1% |
| Tooth Extraction |
3.1% |
| Dyspnoea |
2.7% |
| Intestinal Perforation |
2.7% |
| Nausea |
2.7% |
| Pleural Effusion |
2.7% |
|
| Interacting |
| Rectal Cancer |
28.8% |
| Product Used For Unknown Indication |
26.9% |
| Breast Cancer Metastatic |
21.2% |
| Bone Lesion |
9.6% |
| Breast Cancer |
5.8% |
| Neoplasm Malignant |
5.8% |
| Pain |
1.9% |
|
| Drug Interaction |
16.7% |
| Pancreatitis |
16.7% |
| Blood Bilirubin Increased |
8.3% |
| Blood Creatinine Increased |
8.3% |
| Haematuria |
8.3% |
| Osteonecrosis |
8.3% |
| Rash |
8.3% |
| Renal Failure Acute |
8.3% |
| Renal Impairment |
8.3% |
| Thrombocytopenia |
8.3% |
|
